Skip to main content
Article thumbnail
Location of Repository

Does pharmaceutical price regulation affect the adoption of generic competition?: evidence from the OECD, 1999-2008

By Joan Costa-i-Font, Nebibe Varol and Alistair McGuire


Generic competition in the pharmaceutical market is an effective cost-containment mechanism that improves static efficiency and stimulates pharmaceutical innovation. There is no prior study that has empirically analysed the relative delays in adoption of generic competition. This paper aims to investigate how price regulations in the OECD affect the adoption of generic competition following the first global generic launch of each molecule. Drawing upon data from 1999 to 2008, we estimate the impact of ex-ante price and market size expectations on the probability of generic launch using discrete-time duration modelling with cloglog and logit regressions. The econometric strategy employs both parametric and non-parametric duration dependence and includes controls for generic competition in each country, firm characteristics and molecule heterogeneity. Ex-ante profit expectations result in faster adoption; both expected price and market size increase the probability of launch. Our findings suggest that neither molecule nor firm characteristics have a significant effect on generic adoption across different specifications. Instead, evidence indicates that generic competitors follow a locally oriented strategy in contrast to research-intensive pharmaceutical firms

Topics: RA Public aspects of medicine, RS Pharmacy and materia medica
Publisher: CESifo Group
Year: 2011
OAI identifier:
Provided by: LSE Research Online

Suggested articles


  1. (2000a). "Cross-national Price Differences for Pharmaceuticals: How Large and Why?"
  2. (2000b). "Does Regulation Drive out Competition in Pharmaceutical Markets?"
  3. (2002). Antecedents of international new product rollout timeliness." doi
  4. (2000). Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry." doi
  5. (1992). Brand Loyalty, Entry and Price Competition doi
  6. (2007). Canadian Generic Drug Sector Study.
  7. (2007). Controlling Pharmaceutical Prices and Expenditures. Changing the US Health Care System: Key Issues
  8. (2006). Do Manufacturers of Brand Name Drugs Engage in Price Competition? An Analysis of Introductory Prices." doi
  9. (1997). Drug patent expirations and the speed of generic entry."
  10. (2001). Entry and the number of firms in the Swedish pharmaceuticals market."
  11. (1999). Entry Decisions in the Generic Pharmaceutical Industry." doi
  12. (2007). European Generic Medicines Association doi
  13. (2005). European prices of newly launched reimbursable pharmaceuticals-a pilot study." doi
  14. (2004). Evolving Dynamics of US and European Generics Markets." doi
  15. (2006). Generic competition in the US pharmaceutical industry." doi
  16. (2005). Generic drug industry dynamics." doi
  17. (1997). Generic entry and the pricing of pharmaceuticals." doi
  18. (2009). Generic Entry in a Regulated Pharmaceutical Market " doi
  19. (2009). Generic entry into the regulated spanish pharmaceutical market." doi
  20. (2007). Generic entry, price competition, and market segmentation in the prescription drug market." doi
  21. (2010). Generic Medicine Pricing Policies in Europe: Current Status and Impact." doi
  22. (2000). Generic take-up in the pharmaceutical market following patent expiry A multi-country study." doi
  23. (1994). Generics and new goods in pharmaceutical price indexes." The American Economic Review: doi
  24. (2009). Generics at the crossroads: Will Europe lead the way forward." doi
  25. (2009). How to increase patient access to generic medicines in European Healthcare Systems.
  26. (1993). It's about time: Using discrete-time survival analysis to study duration and the timing of events." doi
  27. (1985). Logistic Regression in Survival Analysis."
  28. (2003). Lowering generic drug prices: less regulation equals more competition." Medical care: doi
  29. (2006). Off-patent drugs in Italy." doi
  30. (1988). Persuasion or Information-Promotion and the Shares of Brand Name and Generic Pharmaceuticals." doi
  31. (2007). Pharmaceutical Price Controls and Entry Strategies." doi
  32. (2003). Pharmaceutical Pricing in a Regulated Market." doi
  33. (2009). Pharmaceutical Sector Inquiry Final Report, Available at: t1.pdf.
  34. (1993). PMA Annual Survey Report: Trends
  35. (1998). Price trends before and after patent expiration in the pharmaceutical industry." doi
  36. (1992). Pricing, Patent Loss and the Market for Pharmaceuticals." doi
  37. (1978). Regression analysis of grouped survival data with application to breast cancer data." doi
  38. (1998). Rolling Out New Products Across Country Markets: An Empirical Study of Causes of Delays." doi
  39. (2005). Survival Analysis, Chapter 3, Available at:
  40. (2006). Sustaining Generic Medicines Markets in Europe. Belgium, Katholieke Universiteit Leuven, Research centre for pharmaceutical care and pharmaco-economics. Available at:
  41. (2006). The changing competitive landscape in the global generics market: Threat or opportunity?" doi
  42. (2002). The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US Pharmaceutical Industry." doi
  43. (2006). The European Generic Pharmaceutical Market in Review: doi
  44. (2001). The impact of generic drug competition on brand name market shares–Evidence from micro data."
  45. (2000). The importance of doctors' and patients' preferences in the prescription decision." doi
  46. (1998). The importance of the physician in the generic versus tradename prescription decision." doi
  47. (2003). Using discrete-time survival analysis to examine patterns of remission from substance use disorder among persons with severe mental illness."
  48. (2007). What is the Value of Authorized Generic Agreements? Assessments on the French Market. ." doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.